Testosterone therapy to restore hormone treatment response in advanced prostate cancer
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial tests if giving testosterone alongside standard hormone therapy can re-sensitize advanced prostate cancer that has stopped responding to treatment. It aims to help patients whose cancer is progressing despite current therapies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older
- You have advanced prostate cancer that is growing despite hormone therapy and low testosterone levels
- You have tried at least one newer hormone-blocking drug (like enzalutamide or abiraterone) and it stopped working
- You have a tumor that can be biopsied (or you have stored tissue from a past biopsy)
- Your kidney and liver function are adequate based on blood tests
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if adding high doses of testosterone to standard chemotherapy (etoposide and carboplatin) can make the chemo work better in men whose prostate cancer has stopped responding to other treatments. It aims to see if this approach can shrink tumors or slow cancer growth.
This trial is for men with metastatic prostate cancer that has already spread beyond the pelvis. It tests whether adding a chemotherapy drug (docetaxel) to the usual hormone therapy plus apalutamide can help control the cancer better than hormone therapy alone.
This trial uses a blood test to measure tumor DNA and see if men with advanced prostate cancer can safely stop treatment with a drug called 177Lu-PSMA-617 earlier than usual, or switch to chemotherapy. It may help reduce side effects while still controlling the cancer.
This trial tests a combination of two treatments for advanced prostate cancer that has stopped responding to hormone therapy. One treatment is a targeted radiation therapy (177Lu-PSMA-617) and the other is an immunotherapy (sipuleucel-T) that helps your immune system fight the cancer.
This Phase 3 trial studies whether using the usual medicines for metastatic prostate cancer, plus a definitive local treatment to the prostate, improves outcomes. It may help determine if treating the prostate directly can benefit people whose cancer has not worsened after initial hormone-based treatment.
This study tests whether testosterone replacement therapy can safely improve low testosterone levels in men with low-risk prostate cancer who are not getting immediate treatment. It aims to help men feel better without worsening their cancer.
Hear when a new Castration-Resistant Prostate Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.